Kingdon Capital Management, L.L.C. Intra Cellular Therapies, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $613 Million
- Q4 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 100,000 shares of ITCI stock, worth $12.8 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$12.8 Million% of portfolio
0.09%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ITCI
# of Institutions
406Shares Held
89MCall Options Held
264KPut Options Held
129K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.24 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$808 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$655 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$415 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$411 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.1B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...